Evidence map›Paper›PMID 26573799›Full record

ArticleCancer research2016

An Effective Immuno-PET Imaging Method to Monitor CD8-Dependent Responses to Immunotherapy.

Richard Tavaré, Helena Escuin-Ordinas, Stephen Mok, Melissa N McCracken, Kirstin A Zettlitz, Felix B Salazar, Owen N Witte, Antoni Ribas, Anna M Wu

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 200 papers.

0numbers the graph read from it
0cells of the map it votes in
200citing papers in PubMed
9.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

200 citing papers in PubMed, 318 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Challenges in tracer development for tumor microenvironment (TME) imaging.European journal of nuclear medicine and molecular imaging · 2026
    Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. SIRPα Immuno-PET Provides a Pan-Myeloid View of Immune Activity During COVID-19.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026
    Article
  12. Npj imaging · 2025
    Article
  13. [European journal of nuclear medicine and molecular imaging · 2025
    Article
  14. Review
  15. Reengineered Anti-CD4 Cys-diabody Variants forMolecular imaging and biology · 2025
    Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article

140 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Richard TavaréCrump Institute for Molecular Imaging, University of California Los Angeles, Los Angeles, California. Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, California. rtavare@mednet.ucla.edu awu@mednet.ucla.edu.
Helena Escuin-OrdinasDepartment of Medicine, Division of Hematology-Oncology, University of California Los Angeles, Los Angeles, California.
Stephen MokDepartment of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, California.
Melissa N McCrackenDepartment of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, California.
Kirstin A ZettlitzCrump Institute for Molecular Imaging, University of California Los Angeles, Los Angeles, California. Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, California.
Felix B SalazarCrump Institute for Molecular Imaging, University of California Los Angeles, Los Angeles, California. Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, California.
Owen N WitteDepartment of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, California. Howard Hughes Medical Institute, University of California Los Angeles, Los Angeles, California. Department of Microbiology, Immunology and Molecular Genetics, University of California Los Angeles, Los Angeles, California. Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California Los Angeles, Los Angeles, California.
Antoni RibasDepartment of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, California. Department of Medicine, Division of Hematology-Oncology, University of California Los Angeles, Los Angeles, California. Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California. Surgery, Division of Surgical Oncology, University of California Los Angeles, Los Angeles, California. Institute for Molecular Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.
Anna M WuCrump Institute for Molecular Imaging, University of California Los Angeles, Los Angeles, California. Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, California. Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California. rtavare@mednet.ucla.edu awu@mednet.ucla.edu.
University of California, Los Angeles · USLos Angeles Medical Center · USHoward Hughes Medical Institute · US

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI JOHN A GLASPY · 1985 to 2026
$134.5M
Transductionally Redirected /Transcriptionally RestricteP50CA086306 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI HERSCHMAN, HARVEY R. · 2000 to 2014
$29.0M
TARGETED COMBINATORIAL TREATMENT OF BRAF MELANOMASP01CA168585 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI RIBAS, ANTONI · 2013 to 2017
$8.4M
UCLA Scholars in Oncologic Molecular lmaging (SOMI)R25CA098010 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI PHELPS, MICHAEL E · 2003 to 2013
$5.0M
In vivo imaging of T Cells using engineered antibodies and PETR21AI114255 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WU, ANNA M · 2014 to 2015
$424k
(PQC4) Imaging CD8 T Cells In Tumor Immunotherapy By ImmunopetR21CA190044 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WU, ANNA M · 2014 to 2015
$368k
Howard Hughes Medical InstituteNCI NIH HHS NIH CA016042NCI NIH HHS NIH R25T CA098010NCI NIH HHS P01 CA168585NCI NIH HHS P30 CA016042NCI NIH HHS P50 CA086306NCI NIH HHS P50 CA168585NCI NIH HHS R21 CA190044NCI NIH HHS R25 CA098010NIAID NIH HHS R21 AI114255
6 · The paper itself

Abstract

The rapidly advancing field of cancer immunotherapy is currently limited by the scarcity of noninvasive and quantitative technologies capable of monitoring the presence and abundance of CD8(+) T cells and other immune cell subsets. In this study, we describe the generation of (89)Zr-desferrioxamine-labeled anti-CD8 cys-diabody ((89)Zr-malDFO-169 cDb) for noninvasive immuno-PET tracking of endogenous CD8(+) T cells. We demonstrate that anti-CD8 immuno-PET is a sensitive tool for detecting changes in systemic and tumor-infiltrating CD8 expression in preclinical syngeneic tumor immunotherapy models including antigen-specific adoptive T-cell transfer, agonistic antibody therapy (anti-CD137/4-1BB), and checkpoint blockade antibody therapy (anti-PD-L1). The ability of anti-CD8 immuno-PET to provide whole body information regarding therapy-induced alterations of this dynamic T-cell population provides new opportunities to evaluate antitumor immune responses of immunotherapies currently being evaluated in the clinic.

Indexed as

AnimalsAntibodies, BispecificCD8 AntigensCD8-Positive T-LymphocytesColonic NeoplasmsDeferoxamineDisease Models, AnimalHumansImmunoconjugatesImmunotherapy, AdoptiveLymphocytes, Tumor-InfiltratingMiceMice, Inbred BALB CMice, Inbred C57BLPositron-Emission TomographyRadioisotopesAntibodies, BispecificCD8 AntigensDeferoxamineImmunoconjugatesRadioisotopesRadiopharmaceuticalsZirconium

Identifiers

PMID26573799
PMCPMC4703530
OpenAlexW2181134504

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.